Key Highlights
- Scientists have genetically analyzed nearly 500 cat tumors and found striking similarities to human cancers.
- The discovery could lead to better treatments for both cats and humans with similar types of cancer.
- Certain chemotherapy drugs appear more effective in cat mammary tumors carrying specific genetic mutations.
Unlocking Cancer Secrets Through Feline Genetics
Imagine a world where understanding feline cancer could unlock new treatments for human patients. This is exactly what scientists have achieved with the largest-ever study on domestic cats’ cancers, published in Science.
A Surprising Genetic Connection
The research, led by Dr. Geoffrey Wood at the University of Guelph and co-authored by Sven Rottenberg from the University of Bern, analyzed nearly 500 tumor samples from cats across five countries. The findings reveal that cat cancers share many dangerous genetic mutations with human cancers, particularly breast cancer.
One of the most significant discoveries was the gene FBXW7, which is frequently altered in feline mammary tumors and also linked to poorer outcomes in human breast cancer patients. This striking similarity suggests a shared biological pathway between the two species.
A Gateway for New Treatments
The genetic insights from this study could pave the way for more effective treatments, both for cats and humans. Dr. Wood points out that “having access to such a large set of donated tissues allowed us to assess drug responses across tumor types in ways not possible before.”
Specifically, certain chemotherapy drugs were found to be more effective in cat mammary tumors with the mutated FBXW7 gene. While these results are observed only in tissue samples for now, they hold promise for future clinical applications.
The One Medicine Approach
This groundbreaking research underscores the One Medicine approach, which encourages the exchange of knowledge between veterinary and medical researchers to improve health outcomes across species. The study brings together experts from institutions like the Wellcome Sanger Institute, Ontario Veterinary College at the University of Guelph, and several additional partners.
The findings suggest that treatments already used in humans could be tested in cats, and vice versa. This collaborative strategy opens doors for precision feline oncology, catching up with diagnostic and therapeutic options available for dogs and potentially even guiding future human clinical research.
Dr.
Van Der Weyden from the Wellcome Sanger Institute concludes that this study “opens the door for future advances in feline cancer care” and paves the way towards more personalized medicine across species.
The research, funded by organizations like EveryCat Health Foundation, CVS Group, Wellcome, and others, marks a significant step forward in understanding and treating cancers. As Dr. Wood notes, “we can now begin to take the next steps towards precision feline oncology.”
